23andMe genetic analysis approved for direct advertising
The FDA just approved direct-to-consumer marketing for genetic risk information (23andMe Personal Genome Service Genetic Health Risk) for 10 conditions, though noting that "the tests cannot determine a person's overall risk of developing a disease or condition ... there are many factors that contribute to the development of a health condition, including environmental and lifestyle factors." This approved test involves saliva samples, assessing more than 500,000 genetic variants associated with increased risk of: Parkinson's disease, late-onset Alzhemer's , Celiac disease, Alpha-1 antitrypsin deficiency, Early-onset primary dystonia, Factor XI deficiency, Gaucher disease type 1, Glucose-6-phosphate dehydrogenase deficiency, Hereditary hemochromatosis, Hereditary thrombophilia. see https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551185.htm The FDA reviewed the data for 23andMe through a premarket review pathway for low-to-moderate risk...